Icosapent Ethyl
CV Risk Reduction (Post-Myocardial Infarction)
Key Facts
About Amarin Corporation
Amarin is a commercial-stage biopharmaceutical company whose mission is to reduce the global burden of cardiovascular disease (CVD). Its primary achievement is the development and commercialization of VASCEPA (icosapent ethyl), which gained a landmark FDA approval for cardiovascular risk reduction based on the pivotal REDUCE-IT outcomes trial. The company's strategy is centered on maximizing the global commercial potential of VASCEPA through geographic expansion, defending its intellectual property, and exploring lifecycle extensions, while its future hinges on navigating generic competition and executing this focused plan.
View full company profileAbout Amarin Corporation
Amarin is a commercial-stage biopharmaceutical company whose mission is to reduce the global burden of cardiovascular disease (CVD). Its primary achievement is the development and commercialization of VASCEPA (icosapent ethyl), which gained a landmark FDA approval for cardiovascular risk reduction based on the pivotal REDUCE-IT outcomes trial. The company's strategy is centered on maximizing the global commercial potential of VASCEPA through geographic expansion, defending its intellectual property, and exploring lifecycle extensions, while its future hinges on navigating generic competition and executing this focused plan.
View full company profile